CT imaging with iopromide liposomes in a rabbit model

Area of Science:

• Radiology
• Nanotechnology
• Pharmacology

Background:

• Computed tomography (CT) imaging relies on contrast agents for enhanced visualization.
• Iopromide is a commonly used iodinated contrast agent.
• Liposomes offer potential for targeted drug delivery and improved imaging characteristics.

Purpose of the Study:

• To evaluate the CT imaging potential of iopromide-carrying liposomes.
• To compare liposomal iopromide with standard iopromide in rabbits with liver tumors.
• To assess lesion detectability and delineation using these contrast agents.

Main Methods:

• Iopromide and iopromide liposomes were administered to healthy and tumor-bearing rabbits.
• CT imaging was performed up to 1 hour post-administration.
• Pharmacokinetic parameters and lesion detectability/delineation were assessed.

Main Results:

• Iopromide liposomes achieved similar blood-pool enhancement as iopromide using half the iodine dose.
• Liver lesion detectability was good in the arterial phase with iopromide but poor in later phases.
• Iopromide liposomes provided long-lasting, good lesion detectability and delineation, comparable or superior to iopromide.

Conclusions:

• Iopromide-carrying liposomes demonstrate significant potential as CT contrast agents.
• Liposomal formulation allows for reduced iodine dose while maintaining or improving imaging performance.
• This approach may enhance the detection and characterization of liver lesions in CT imaging.